Pasithea Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Pasithea Therapeutics şirketinin toplam hissedar öz sermayesi $17.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $18.6M ve $824.0K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$9.36m
Eşitlik	US$17.81m
Toplam yükümlülükler	US$823.98k
Toplam varlıklar	US$18.64m

Son finansal sağlık güncellemeleri

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06

Recent updates

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: KTTA 'nin kısa vadeli varlıkları ( $9.8M ) kısa vadeli yükümlülüklerini ( $660.4K ) aşıyor.

Uzun Vadeli Yükümlülükler: KTTA şirketinin kısa vadeli varlıkları ( $9.8M ) uzun vadeli yükümlülüklerini ( $163.6K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: KTTA borçsuzdur.

Borcun Azaltılması: KTTA un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: KTTA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: KTTA un, serbest nakit akışı her yıl % 45.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Pasithea Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Recent updates

Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million.

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

New major risk - Financial position

Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

New minor risk - Share price stability

Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024

Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients

New major risk - Financial position

Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate

Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023

High number of new and inexperienced directors

Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.

New major risk - Share price stability

Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.

Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea Therapeutics

Price target decreased to US$2.30

Less than half of directors are independent

Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp

Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek Therapeutics

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.

Camac Partners LLC Sends a Letter to Pasithea Therapeutics Corp

Less than half of directors are independent

Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of Directors

Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory Board

Camac Partners Provides Information to Shareholders of Pasithea Therapeutics

Camac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special Meeting

Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics Corp

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes Away

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory Board

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

Pasithea Therapeutics Corp. announced that it has received $30.38 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in funding

Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.K

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin